-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] On March 17, Yunnan Baiyao issued the "Announcement on the Progress of Major Asset Purchases and Related Transactions", and planned to participate in the subscription of 6.
66 A shares of Shanghai Pharmaceuticals with a price of not more than 11.
23 billion yuan, accounting for 6.
66 shares of Shanghai Pharmaceuticals after the issuance.
18.
02% of the total share capital
.
From the perspective of public information, as early as May 2021, Shanghai Pharmaceuticals disclosed a fixed increase plan, and planned to issue shares to Shanghai Tandong and Yunnan Baiyao to raise no more than 14.
384 billion yuan, of which Yunnan Baiyao, as a strategic investor, plans to subscribe for More than 11.
229 billion yuan
.
It is understood that the transaction proposal Yunnan Baiyao was reviewed on June 7, 2021, and passed on June 10 of that year
.
On March 15 this year, Shanghai Pharmaceuticals issued a "Progress Notification Letter" to Yunnan Baiyao, indicating that the Issuance Review Committee of the China Securities Regulatory Commission reviewed Shanghai Pharmaceuticals' application for non-public issuance of A shares in 2021 on March 14, 2022
.
According to the review results of the meeting, Shanghai Pharma's application for the non-public issuance of A shares was approved
.
According to the data, Yunnan Baiyao is a head company of traditional Chinese medicine.
Since the mixed reform in 2016, in addition to the traditional medicine business, Yunnan Baiyao has continued to cross over to other fields, involving health products, tea products, industrial hemp, medical beauty and other businesses
.
At the same time, the company has increased its efforts in securities investment since 2019, including Xiaomi Group, Tencent Holdings, Hengrui Medicine, China Antibody, etc.
, which have become the investment targets of Yunnan Baiyao
.
Data shows that Yunnan Baiyao's net profit in 2019 and 2020 totaled 9.
7 billion yuan, and investment income accounted for more than 44%
.
Shanghai Pharmaceuticals is a leading pharmaceutical distribution company whose main business covers pharmaceutical R&D and pharmaceuticals, distribution and retail
.
In the first three quarters, the company achieved operating income of 160.
973 billion yuan, a year-on-year increase of 14.
72%; net profit attributable to the parent reached 4.
484 billion yuan, a year-on-year increase of 24.
49%
.
Among them, the first three quarters were mainly contributed by the main business of pharmaceutical business and pharmaceutical industry, which were 2.
082 billion yuan and 1.
679 billion yuan respectively
.
The third quarterly report shows that the company's pharmaceutical business has a solid position, and has initially built a unique differentiated advantage in the competition.
The pharmaceutical industry business is in a stage of active innovation and transformation.
The promotion of innovative drug pipelines and overseas authorization accelerate the process of internationalization.
and so on is taking a step by step
.
The industry said that from the perspective of the general environment, pharmaceutical distribution companies are often the objects of being "squeezed" by upstream and downstream.
For upstream, they need to cooperate with manufacturers to ensure product supply; for downstream, it is necessary to conduct sales network layout and comprehensively establish Partnerships with various medical institutions
.
In recent years, with the advancement of medical reform and medical insurance cost control, the payment of downstream medical institutions to upstream pharmaceutical distribution enterprises has been continuously delayed
.
Therefore, the capital needs of pharmaceutical distribution enterprises are more urgent
.
The data shows that Shanghai Pharmaceutical's accounts receivable turnover rate has dropped from 4.
33 times in 2018 to 3.
83 times in 2020, a drop of 12%
.
According to industry estimates, from 2018 to 2020, Shanghai Pharmaceuticals has a cumulative funding gap of about 78.
7 billion yuan
.
However, under heavy pressure, Shanghai Pharmaceuticals has continued to increase R&D investment in recent years for innovative drug R&D, secondary development, consistency evaluation, generic drug category 3/4, and APIs
.
From 2018 to 2020, the company invested a total of 4.
9 billion yuan in research and development expenses, with an average annual compound growth rate of 19%
.
In addition, in the first three quarters of 2021, the research and development expenses of Shanghai Pharmaceuticals reached 1.
367 billion yuan, a year-on-year increase of 31.
38%
.
Yunnan Baiyao's overweight in the field of pharmaceutical distribution is a manifestation of the upstream and downstream cooperation of the enterprise in the industrial chain
.
The industry believes that after Yunnan Baiyao joins Shanghai Pharmaceuticals, it will bring benefits such as channel complementarity and raw material supply support, or help Shanghai Pharmaceuticals to solve financial difficulties to a certain extent
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
66 A shares of Shanghai Pharmaceuticals with a price of not more than 11.
23 billion yuan, accounting for 6.
66 shares of Shanghai Pharmaceuticals after the issuance.
18.
02% of the total share capital
.
From the perspective of public information, as early as May 2021, Shanghai Pharmaceuticals disclosed a fixed increase plan, and planned to issue shares to Shanghai Tandong and Yunnan Baiyao to raise no more than 14.
384 billion yuan, of which Yunnan Baiyao, as a strategic investor, plans to subscribe for More than 11.
229 billion yuan
.
It is understood that the transaction proposal Yunnan Baiyao was reviewed on June 7, 2021, and passed on June 10 of that year
.
On March 15 this year, Shanghai Pharmaceuticals issued a "Progress Notification Letter" to Yunnan Baiyao, indicating that the Issuance Review Committee of the China Securities Regulatory Commission reviewed Shanghai Pharmaceuticals' application for non-public issuance of A shares in 2021 on March 14, 2022
.
According to the review results of the meeting, Shanghai Pharma's application for the non-public issuance of A shares was approved
.
According to the data, Yunnan Baiyao is a head company of traditional Chinese medicine.
Since the mixed reform in 2016, in addition to the traditional medicine business, Yunnan Baiyao has continued to cross over to other fields, involving health products, tea products, industrial hemp, medical beauty and other businesses
.
At the same time, the company has increased its efforts in securities investment since 2019, including Xiaomi Group, Tencent Holdings, Hengrui Medicine, China Antibody, etc.
, which have become the investment targets of Yunnan Baiyao
.
Data shows that Yunnan Baiyao's net profit in 2019 and 2020 totaled 9.
7 billion yuan, and investment income accounted for more than 44%
.
Shanghai Pharmaceuticals is a leading pharmaceutical distribution company whose main business covers pharmaceutical R&D and pharmaceuticals, distribution and retail
.
In the first three quarters, the company achieved operating income of 160.
973 billion yuan, a year-on-year increase of 14.
72%; net profit attributable to the parent reached 4.
484 billion yuan, a year-on-year increase of 24.
49%
.
Among them, the first three quarters were mainly contributed by the main business of pharmaceutical business and pharmaceutical industry, which were 2.
082 billion yuan and 1.
679 billion yuan respectively
.
The third quarterly report shows that the company's pharmaceutical business has a solid position, and has initially built a unique differentiated advantage in the competition.
The pharmaceutical industry business is in a stage of active innovation and transformation.
The promotion of innovative drug pipelines and overseas authorization accelerate the process of internationalization.
and so on is taking a step by step
.
The industry said that from the perspective of the general environment, pharmaceutical distribution companies are often the objects of being "squeezed" by upstream and downstream.
For upstream, they need to cooperate with manufacturers to ensure product supply; for downstream, it is necessary to conduct sales network layout and comprehensively establish Partnerships with various medical institutions
.
In recent years, with the advancement of medical reform and medical insurance cost control, the payment of downstream medical institutions to upstream pharmaceutical distribution enterprises has been continuously delayed
.
Therefore, the capital needs of pharmaceutical distribution enterprises are more urgent
.
The data shows that Shanghai Pharmaceutical's accounts receivable turnover rate has dropped from 4.
33 times in 2018 to 3.
83 times in 2020, a drop of 12%
.
According to industry estimates, from 2018 to 2020, Shanghai Pharmaceuticals has a cumulative funding gap of about 78.
7 billion yuan
.
However, under heavy pressure, Shanghai Pharmaceuticals has continued to increase R&D investment in recent years for innovative drug R&D, secondary development, consistency evaluation, generic drug category 3/4, and APIs
.
From 2018 to 2020, the company invested a total of 4.
9 billion yuan in research and development expenses, with an average annual compound growth rate of 19%
.
In addition, in the first three quarters of 2021, the research and development expenses of Shanghai Pharmaceuticals reached 1.
367 billion yuan, a year-on-year increase of 31.
38%
.
Yunnan Baiyao's overweight in the field of pharmaceutical distribution is a manifestation of the upstream and downstream cooperation of the enterprise in the industrial chain
.
The industry believes that after Yunnan Baiyao joins Shanghai Pharmaceuticals, it will bring benefits such as channel complementarity and raw material supply support, or help Shanghai Pharmaceuticals to solve financial difficulties to a certain extent
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
